2B4 Stock Overview
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr20.30 |
| 52 Week High | kr21.62 |
| 52 Week Low | kr7.78 |
| Beta | 1.03 |
| 1 Month Change | 6.79% |
| 3 Month Change | 19.41% |
| 1 Year Change | 156.31% |
| 3 Year Change | 221.20% |
| 5 Year Change | 880.68% |
| Change since IPO | 587.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2B4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.7% | -4.3% | -2.5% |
| 1Y | 156.3% | -19.4% | -0.4% |
Return vs Industry: 2B4 exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 2B4 exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| 2B4 volatility | |
|---|---|
| 2B4 Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2B4 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2B4's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 110 | Emil Billbäck | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes.
Bonesupport Holding AB (publ) Fundamentals Summary
| 2B4 fundamental statistics | |
|---|---|
| Market cap | €1.34b |
| Earnings (TTM) | €20.99m |
| Revenue (TTM) | €50.64m |
63.7x
P/E Ratio26.4x
P/S RatioIs 2B4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2B4 income statement (TTM) | |
|---|---|
| Revenue | kr591.08m |
| Cost of Revenue | kr50.16m |
| Gross Profit | kr540.92m |
| Other Expenses | kr295.90m |
| Earnings | kr245.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 3.73 |
| Gross Margin | 91.51% |
| Net Profit Margin | 41.45% |
| Debt/Equity Ratio | 0% |
How did 2B4 perform over the long term?
See historical performance and comparison